Targets › MAPK8IP3
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Feb 2027.
The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity). (UniProt, Q9UPT6)
Open in Phaseline: the race on MAPK8IP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| n-Lorem Foundation | nL-MAPK8-001 Antisense oligonucleotide targeting MAPK8IP3 | MAPK8IP3 | Phase 1 | Neurodevelopmental Disorder With or Without Variable Brain Abnormalities | Feb 2027 |
Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (1)
small molecule (1)
n-Lorem Foundation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.